Evidence map›Paper›PMID 35507280›Full record

ReviewCurrent atherosclerosis reports2022

Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease.

Nicholas W S Chew, Cheng Han Ng, Mark Dhinesh Muthiah, Arun J Sanyal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Editorial: The heart of NAFLD.Frontiers in medicine · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Nicholas W S ChewDepartment of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore. nicholas_ws_chew@nuhs.edu.sg.ORCID 0000-0002-0640-0430
Cheng Han NgYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Mark Dhinesh MuthiahDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Arun J SanyalDivision of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, VA, 23298-0341, USA. arun.sanyal@vcuhealth.org.
National University Heart Centre Singapore · SGNational University Hospital · SGNational University of Singapore · SGVirginia Commonwealth University · US

Funding

LIPIDOMICS BASED DIAGNOSTICS FOR NONALCOHOLIC STEATOHEPATITISR01DK105961 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENNIS, EDWARD A, SANYAL, ARUN J · 2015 to 2018
$2.8M
NIDDK NIH HHS R01 DK105961
6 · The paper itself

Abstract

purpose of reviewThe global prevalence of non-alcoholic fatty liver disease (NAFLD) presents an unmet need in treating these, often asymptomatic, individuals. In this review, we summarised NAFLD management and described recent developments in non-alcoholic steatohepatitis (NASH) therapeutics that can shape the future of NAFLD. RECENT

findingsA multi-disciplinary effort in promoting sustainable lifestyle measures is paramount, with the goal of either limiting energy surplus alone or in combination with targeting downstream pathways of inflammation and fibrosis. Several antidiabetic medications like PPAR-γ agonist and glucagon-like peptide receptor agonists have beneficial effects on the metabolic profile as well as NASH histology. Vitamin E has shown promise in specific groups of patients with the haptoglobin2 allele protein. Newer drugs have demonstrated promising results in NASH resolution and fibrosis improvement such as obeticholic acid, resmetirom, aramchol, efruxifermin, aldafermin and lanifibranor. Apart from discussing the results of late stage clinical trials and the possible challenges in managing these patients with limited approved therapies, we also discussed the specific management of comorbidities (diabetes, hypertension, hyperlipidaemia, cardiovascular diseases) in NAFLD patients. Treatment strategy needs to target improvements in liver-related outcomes and cardiometabolic profile.

Indexed as

Cardiovascular DiseasesNon-alcoholic Fatty Liver DiseaseFibrosisHolistic HealthHumansHypoglycemic AgentsLiverHypoglycemic AgentsInterventionNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisPharmacology

Identifiers

PMID35507280
OpenAlexW4225428071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.